Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

WellSpan-THRIVE Cancer QOL Study

for
Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative,
Location: Ephrata PA, Lebanon PA, York PA, Gettysburg PA,
Sponsor: WellSpan Health

Sex: All

Age: 18+

Code: NCT07433660

Recruiting

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

for
Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT07280312

Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

for
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT03412877

Phase 2, Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

for
Breast Cancer, Breast Cancer Metastatic,
Location: Boston MA, Durham NC, Buffalo NY, Orlando FL,
Sponsor: Incyclix Bio

Sex: All

Age: 18+

Code: NCT05735080

Phase 1, Phase 2, Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: 858 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06395519

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

for
Endometrioid Cancer, Mucinous Ovarian Cancer,
Location: Orlando FL, New Orleans LA, Oklahoma City OK,
Sponsor: University of Oklahoma

Sex: Female

Age: 18 - 70+

Code: NCT05512208

Phase 2, Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

for
Advanced Endometrial Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05039801

Phase 1, Recruiting
New

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

for
Locally Advanced /Metastatic Solid Tumors,
Location: Houston TX
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT07940881

Phase 1, Recruiting
New

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

for
Locally Advanced /Metastatic Solid Tumors,
Location: Orlando FL, Sarasota FL, Nashville TN, Dallas TX
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT07857616

Phase 1, Recruiting

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

for
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT03604315

Phase 1, Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

for
Advanced Solid Tumor, Metastatic Solid Tumor,
Location: New York NY, Jacksonville FL, Cleveland OH,
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT05824975

Phase 1, Phase 2, Recruiting

Circulating Tumor DNA Exposure in Peripheral Blood

for
Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer,
Location: Orlando FL, Celebration FL, Centerville OH, Dayton OH
Sponsor: Quantgene Inc.

Sex: All

Age: 18+

Code: NCT03517332

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

for
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma,
Location: Chicago IL
Sponsor: Northwestern University

Sex: All

Age: 18+

Code: NCT05733000

Phase 2, Recruiting

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

for
Cervical Carcinoma, Fallopian Tube Carcinoma,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT06492070

Phase 2, Recruiting

Questionnaire Study for Gynecological Cancer Survivors

for
Endometrial Neoplasms, Ovarian Neoplasms,
Location: Washington DC
Sponsor: U.S. Army Medical Research and Development Command

Sex: Female

Age: 20 - 70+

Code: NCT00391664

Recruiting

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

for
Malignant Female Reproductive System Neoplasm,
Location: Baltimore MD, Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT03968406

Phase 1, Recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

for
Non-small Cell Lung Cancer,
Location: Boston MA, New York NY, New Brunswick NJ, Pittsburgh PA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05877599

Phase 1, Recruiting

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

for
Colitis, Diarrhea, Malignant Genitourinary System Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04038619

Phase 1, Recruiting

Access to Genetic Testing in Underserved Patients With Cancer

for
Breast Carcinoma, Male Breast Carcinoma,
Location: Rochester NY, Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18+

Code: NCT06422455

Recruiting

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for
Ovarian Cancer, Solid Tumor
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: OnCusp Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06234423

Phase 1, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial